

## 1ª Convocatoria de "Acceso competitivo" a NANBIOSIS de 2024

### Acuerdo de Priorización de Solicitudes de Acceso a NANBIOSIS

#### por del Comité de Coordinación

NANBIOSIS ofrece acceso a sus servicios a todos los usuarios, nacionales e internacionales, que pueden provenir del sector público o privado, bajo las modalidades de "Acceso Abierto Competitivo" o "Acceso por Demanda". Las solicitudes de acceso seleccionadas en el modo abierto y competitivo obtendrán prioridad en el acceso a la instalación frente a las solicitudes consideradas en "acceso por demanda". Existen dos convocatorias anuales de acceso competitivo.

El proceso de evaluación de dichas solicitudes se lleva a cabo en tres fases:

- Fase interna: Revisión administrativa interna y consulta con las unidades sobre la viabilidad técnica de los accesos solicitados
- Fase externa: Evaluación por el Comité de Acceso
- Priorización de solicitudes en régimen de acceso competitivo por el Comité de Coordinación de NANBIOSIS

En el marco de la 1ª Convocatoria de Acceso Abierto y Competitivo a la ICTS NANBIOSIS en 2024, el Comité de Coordinación de NANBIOSIS, siguiendo la evaluación de solicitudes y la propuesta de priorización emitida por del Comité de Acceso, acuerda:

- Conceder acceso priorizado en "modo abierto y competitivo" a las solicitudes cuyo código de entrada se destaca con fondo verde en la tabla que se muestra a continuación.
- Establecer un orden de prioridad de acceso de dichas solicitudes en modo competitivo, a cada una de las unidades de NANBIOSIS. (Ordenadas de mayor a menor prioridad en la siguiente tabla).
- Considerar como "accesos a demanda" los indicados en las solicitudes cuyo código de entrada tiene fondo blanco en la siguiente tabla. Los accesos derivados de las solicitudes a demanda solo se realizarán una vez cubiertos los "accesos competitivos".

### Priorización de Solicitudes de Acceso a NANBIOSIS

Unidad	Solicitud	Descripción Acceso
U1 (con U30)	3668	U1-S1. Molecular cloning (On-site&Remote) OUTSTANDING, U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING
U1, (con U3, U6, U7, U8, U10, U18, U19, U20)	3522	U1-S1. Molecular cloning (On-site&Remote) OUTSTANDING, U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING, U1-S4: Consultancy in protein production (On-site&Remote)

U1	3621	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING
U1	3637	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
U1	3560	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING
U1	3563	U1-S1. Molecular cloning (On-site&Remote) OUTSTANDING, U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING
U1 (con U30)	3716	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
U1	3620	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING
U1	3536	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
U1	3564	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
U1	3622	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING
U1	3667	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING
U1	3673	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U2	3568	U2-S6. Hybridoma cell culture antibody production (Remote) OUTSTANDING, U2-S7. Antibody purification (Remote) OUTSTANDING, U2-S8. Immunochemical methods development (Remote) OUTSTANDING
U2	3587	U2-S7. Antibody purification (Remote) OUTSTANDING
U2	3588	U2-S4. Polyclonal Antibody Production (Remote) OUTSTANDING
U2	3689	U2-S5. Monoclonal Antibody development (Remote) OUTSTANDING, U2-S6. Hybridoma cell culture antibody production (Remote) OUTSTANDING, U2-S3. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S4. Polyclonal Antibody Production (Remote) OUTSTANDING
U02 (con U3)	3679	U2-S3. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S5. Monoclonal Antibody development (Remote) OUTSTANDING
U02 (con U3)	3680	U2-S3. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S5. Monoclonal Antibody development (Remote) OUTSTANDING
U02 (con U3)	3681	U2-S3. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING
U02 (con U3)	3719	U2-S5. Monoclonal Antibody development (Remote) OUTSTANDING
U02 (con U3)	3723	U2-S4. Polyclonal Antibody Production (Remote) OUTSTANDING
U02 (con U3)	3725	U2-S7. Antibody purification (Remote) OUTSTANDING
U2	3570	U2-S2. Hapten synthesis (Remote) OUTSTANDING, U2-S3. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S6. Hybridoma cell culture antibody production (Remote) OUTSTANDING, U2-S7. Antibody purification (Remote) OUTSTANDING
U2	3572	U2-S6. Hybridoma cell culture antibody production (Remote) OUTSTANDING, U2-S7. Antibody purification (Remote) OUTSTANDING
U2	3577	U2-S7. Antibody purification (Remote) OUTSTANDING
U2	3580	U2-S7. Antibody purification (Remote) OUTSTANDING
U2	3581	U2-S8. Immunochemical methods development (Remote) OUTSTANDING
U2	3631	U2-S5. Monoclonal Antibody development (Remote) OUTSTANDING
U2	3632	U2-S5. Monoclonal Antibody development (Remote) OUTSTANDING

U2	3567	U2-S5. Monoclonal Antibody development (Remote) OUTSTANDING
U2	3582	U2-S6. Hybridoma cell culture antibody production (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U3 (con U1, U6, U7, U8, U10, U18, U19, U20)	3522	U3-S1. Synthesis of peptides and characterization (On-site&Remote) OUTSTANDING, U3-S2. Modification of the peptides (On-site&Remote) OUTSTANDING, U3-S3. Special amino acids for peptide synthesis (Remote) OUTSTANDING
U3	3714	U3-S2. Modification of the peptides (On-site&Remote) OUTSTANDING
U3	3718	U3-S1. Synthesis of peptides and characterization (On-site&Remote) OUTSTANDING, U3-S2. Modification of the peptides (On-site&Remote) OUTSTANDING
U3	3721	U3-S1. Synthesis of peptides and characterization (On-site&Remote) OUTSTANDING, U3-S2. Modification of the peptides (On-site&Remote) OUTSTANDING
U3	3724	U3-S1. Synthesis of peptides and characterization (On-site&Remote) OUTSTANDING, U3-S2. Modification of the peptides (On-site&Remote) OUTSTANDING
U3 (con U2)	3679	U3-S1. Synthesis of peptides and characterization (On-site&Remote) OUTSTANDING
U3 (con U2)	3680	U3-S1. Synthesis of peptides and characterization (On-site&Remote) OUTSTANDING
U3 (con U2)	3681	U3-S1. Synthesis of peptides and characterization (On-site&Remote) OUTSTANDING
U3 (con U2)	3719	U3-S1. Synthesis of peptides and characterization (On-site&Remote) OUTSTANDING
U3 (con U2)	3723	U3-S1. Synthesis of peptides and characterization (On-site&Remote) OUTSTANDING
U3 (con U2)	3725	U3-S1. Synthesis of peptides and characterization (On-site&Remote) OUTSTANDING
U3	3671	U3-S1. Synthesis of peptides and characterization (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U6 (con U20)	3694	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U6 (con U16)	3729	U6-S1. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U6 (con U1, U3, U7, U8, U10, U18, U19, U20)	3522	U6-S6. Fluorescence spectroscopic analysis (On-site&Remote) , U6-S7. UV-Vis spectroscopic analysis (On-site&Remote)
U6	3542	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U6	3627	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING

U6	3715	U6-S1. Use of a High-pressure laboratory-scale plant with 50, 100, and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S2. High-pressure phase analysis – solubility, emulsification OUTSTANDING, U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U6	3717	U6-S1. Use of a High-pressure laboratory-scale plant with 50, 100, and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S2. High-pressure phase analysis – solubility, emulsification OUTSTANDING, U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U6	3545	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U6	3531	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U6	3532	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U6	3603	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U6	3651	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U6	3670	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U6	3676	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
U6	3678	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U7 (con U1, U3, U6, U8, U10, U18, U19, U20)	3522	U7-S9. Thin layer deposition (Remote) OUTSTANDING
U7	3555	U7-S1. Training Courses in the Use of Nanotechnology Equipment (Onsite)
U7	3628	U7-S1. Training Courses in the Use of Nanotechnology Equipment (Onsite), U7-S3. Characterization by SEM (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U8 (con U1, U3, U6, U7, U10, U18, U19, U20)	3522	U8-S01. Design, fabrication, and encapsulation of microelectrodes (based on gold or platinum) on different rigid (Si, SiC or Pyrex) or flexible polymeric substrates (On-site&Remote) OUTSTANDING, U8-S02. Electrochemical and electrical characterization of the microelectrodes mentioned above (On-site&Remote) OUTSTANDING, U8-S05 Deposition of thin films (Polyimide, Parylene) for the fabrication of flexible devices or encapsulation purposes (On-site&Remote) OUTSTANDING, U8-S06 Encapsulation or fabrication of 3D structures via 3D printing
U8	3592	U8-S01. Design, fabrication, and encapsulation of microelectrodes (based on gold or platinum) on different rigid (Si, SiC or Pyrex) or flexible polymeric substrates (On-site&Remote) OUTSTANDING, U8-S05 Deposition of thin films (Polyimide, Parylene) for the fabrication of flexible devices or encapsulation purposes (On-site&Remote) OUTSTANDING

U8	3619	U8-S02. Electrochemical and electrical characterization of the above-mentioned microelectrodes (On-site&Remote) OUTSTANDING
U8	3625	U8-S01. Design, fabrication, and encapsulation of microelectrodes (based on gold or platinum) on different rigid (Si, SiC or Pyrex) or flexible polymeric substrates (On-site&Remote) OUTSTANDING, U8-S02. Electrochemical and electrical characterization of the above-mentioned microelectrodes (On-site&Remote) OUTSTANDING, U8-S04. Graphene growth services (On-site&Remote) OUTSTANDING, U8-S05 Deposition of thin films (Polyimide, Parylene) for the fabrication of flexible devices or encapsulation purposes (On-site&Remote) OUTSTANDING
U8	3626	U8-S01. Design, fabrication, and encapsulation of microelectrodes (based on gold or platinum) on different rigid (Si, SiC or Pyrex) or flexible polymeric substrates (On-site&Remote) OUTSTANDING, U8-S02. Electrochemical and electrical characterization of the microelectrodes mentioned above (On-site&Remote) OUTSTANDING, U8-S04. Graphene growth services (On-site&Remote) OUTSTANDING, U8-S05 Deposition of thin films (Polyimide, Parylene) for the fabrication of flexible devices or encapsulation purposes (On-site&Remote) OUTSTANDING
U8	3641	U8-S04. Graphene growth services (On-site&Remote) OUTSTANDING
U8	3728	U8-S01. Design, fabrication, and encapsulation of microelectrodes (based on gold or platinum) on different rigid (Si, SiC or Pyrex) or flexible polymeric substrates (On-site&Remote) OUTSTANDING
U8	3674	U8-S05 Deposition of thin films (Polyimide, Parylene) for the fabrication of flexible devices or encapsulation purposes (On-site&Remote) OUTSTANDING
U8	3675	U8-S06 Encapsulation or fabrication of 3D structures via 3D printing

Unidad	Solicitud	Descripción Acceso
U9	3731	U9-S01. Synthesis of NPs by laser induced-pyrolysis (Remote) OUTSTANDING, U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
U9	3730	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U10 (con U1, U3, U6, U7, U8 U10, U18, U19, U20)	3522	U10-S01. Design & Development of pharmaceutical forms (Remote) OUTSTANDING, U10-S02. Design & Development of micro- & nanocapsules (Remote) OUTSTANDING, U10-S03. Design & Development of solid lipid nanoparticles (SLN) (Remote) OUTSTANDING, U10-S05. Biopharmaceutical evaluation of dosage forms (Remote) OUTSTANDING, U10-S06. Setup and validation of analytical techniques (Remote) OUTSTANDING, U10-S07. Pharmacokinetic pre-clinical studies (Remote) OUTSTANDING
U10	3516	U10-S02. Design & Development of micro- & nanocapsules (Remote) OUTSTANDING
U10	3544	U10-S04. Design & Development of living cells containing microparticles (Remote) OUTSTANDING
U10	3551	U10-S04. Design & Development of living cells containing microparticles (Remote) OUTSTANDING

U10	3576	U10-S08. 3D bio-impression of scaffolding for regenerative medicine (On-site&Remote) OUTSTANDING
U10	3578	U10-S01. Design & Development of pharmaceutical forms (Remote) OUTSTANDING, U10-S03. Design & Development of solid lipid nanoparticles (SLN) (Remote) OUTSTANDING, U10-S05. Biopharmaceutical evaluation of dosage forms (Remote) OUTSTANDING
U10	3591	U10-S08. 3D bio-impression of scaffolding for regenerative medicine (On-site&Remote) OUTSTANDING
U10	3611	U10-S01. Design & Development of pharmaceutical forms (Remote) OUTSTANDING, U10-S02. Design & Development of micro- & nanocapsules (Remote) OUTSTANDING, U10-S03. Design & Development of solid lipid nanoparticles (SLN) (Remote) OUTSTANDING, U10-S06. Setup and validation of analytical techniques (Remote) OUTSTANDING
U10	3590	U10-S01. Design & Development of pharmaceutical forms (Remote) OUTSTANDING, U10-S03. Design & Development of solid lipid nanoparticles (SLN) (Remote) OUTSTANDING, U10-S08. 3D bio-impression of scaffolding for regenerative medicine (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U12	3528	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING, U12-S08. Characterization of materials by high-resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING
U12	3529	U12-S04. Rheology, viscometry, and densimetry (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING, U12-S08. Characterization of materials by high-resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING
U12	3559	U12-S04. Rheology, viscometry, and densimetry (Remote) OUTSTANDING
U12	3565	U12-S06. Contact angle and wettability (Remote) OUTSTANDING, U12-S08. Characterization of materials by high-resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING
U12	3653	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING
U12	3530	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING, U12-S04. Rheology, viscometry, and densimetry (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING
U12	3589	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING, U12-S08. Characterization of materials by high-resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U13	3708	U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S09. COMPRESSION-SHEAR TEST CELLSCALE Micro Tester G2 (On-site) OUTSTANDING

U13	3709	U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING
U13	3710	U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING
U13	3712	U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S09. COMPRESSION-SHEAR TEST CELLSCALE Micro Tester G2 (On-site) OUTSTANDING
U13	3713	U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING
U13	3711	U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S09. COMPRESSION-SHEAR TEST CELLSCALE Micro Tester G2 (On-site) OUTSTANDING
U13	3523	U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING
U13	3552	U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U14 (con U21, U22, U24)	3517	U14-S01. Cell cultures (On-site&Remote) OUTSTANDING
U14 (con U19, U21, U22, U24)	3585	U14-S01. Cell cultures (On-site&Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site&Remote) OUTSTANDING, U14-S4. Cytokine quantification assays (On-site&Remote) OUTSTANDING, U14-S5. Determination of cytokine concentration by flow cytometry (On-site&Remote) OUTSTANDING, U14-S6. Lymphocyte proliferation assay (On-site&Remote) OUTSTANDING
U14 (U19, U21, U22, U24)	3586	U14-S01. Cell cultures (On-site&Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site&Remote) OUTSTANDING, U14-S4. Cytokine quantification assays (On-site&Remote) OUTSTANDING, U14-S5. Determination of cytokine concentration by flow cytometry (On-site&Remote) OUTSTANDING, U14-S6. Lymphocyte proliferation assay (On-site&Remote) OUTSTANDING
U14	3584	U14-S01. Cell cultures (On-site&Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site&Remote) OUTSTANDING, U14-S4. Cytokine quantification assays (On-site&Remote) OUTSTANDING, U14-S5. Determination of cytokine concentration by flow cytometry (On-site&Remote) OUTSTANDING, U14-S6. Lymphocyte proliferation assay (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U16 (con U6)	3729	U16-S07. Evaluation of the adhesion capacities and formation of biolayers of microorganisms on materials. OUTSTANDING
U16	3605	U16-S04. Characterization by Tof-SIM (Remote) OUTSTANDING

U16	3594	U16-S08. Evaluation in percentages of the elemental composition of surfaces - except H and He-, even with deep profiling
U16	3596	U16-S08. Evaluation in percentages of the elemental composition of surfaces - except H and He-, even with deep profiling
U16	3598	U16-S08. Evaluation in percentages of the elemental composition of surfaces - except H and He-, even with deep profiling
U16	3599	U16-S08. Evaluation in percentages of the elemental composition of surfaces - except H and He-, even with deep profiling
U16	3604	U16-S04. Characterization by Tof-SIM (Remote) OUTSTANDING
U16	3606	U16-S08. Evaluation in percentages of the elemental composition of surfaces - except H and He-, even with deep profiling

Unidad	Solicitud	Descripción Acceso
U17	3518	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3538	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3548	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3550	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3662	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3666	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3669	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3607	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3549	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3654	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3655	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
U17	3677	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U18 (con U1, U3, U6, U7, U8, U10, U19, U20)	3522	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (On-site&Remote) OUTSTANDING
U18	3633	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (On-site&Remote) OUTSTANDING
U18	3636	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (On-site&Remote) OUTSTANDING
U18	3690	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (On-site&Remote) OUTSTANDING
U18	3691	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (On-site&Remote) OUTSTANDING
U18	3692	U18-S01. IN VITRO NANOTOXICOLOGY (Remote) OUTSTANDING
U18	3696	U18-S01. IN VITRO NANOTOXICOLOGY (Remote) OUTSTANDING
U18	3556	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3557	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING



U18	3558	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3561	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING
U18	3562	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U19 (con U1, U3, U6, U7, U8, U10, U18, U20)	3522	U19-S01. Preclinical Studies (On-site&Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING, U19-S04. Magistral formulation (Remote)
U19 (con U21, U22)	3623	U19-S01. Preclinical Studies (On-site&Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING, U19-S04. Magistral formulation (Remote)
U19 (con U21, U22)	3624	U19-S01. Preclinical Studies (On-site&Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING, U19-S04. Magistral formulation (Remote)
U19 (con U14, U21, U22, U24)	3585	U19-S01. Preclinical Studies (On-site&Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING, U19-S04. Magistral formulation (Remote)
U19 (con U14, U21, U22, U24)	3586	U19-S01. Preclinical Studies (On-site&Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING
U19 (con U21, U22)	3648	U19-S01. Preclinical Studies (On-site&Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING, U19-S04. Magistral formulation (Remote)
U19 (con U21, U22)	3649	U19-S01. Preclinical Studies (On-site&Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING, U19-S04. Magistral formulation (Remote)

Unidad	Solicitud	Descripción Acceso
U20 (con U6)	3694	U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING, U20-S04. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING, U20-S07. In vivo PK/PD assays (Remote) OUTSTANDING, U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING
U20 (con U1, U3, U6, U7, U8, U10, U18, U19)	3522	U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING, U20-S04. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING, U20-S05. In vivo Toxicology (On-site&Remote) OUTSTANDING, U20-S06. In vivo ADME and biodistribution assays (Remote) OUTSTANDING, U20-S07. In vivo PK/PD assays (Remote) OUTSTANDING, U20-S08. Immunotoxicity assays (On-site&Remote) OUTSTANDING, U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING, U20-S12. Immunohistochemistry on histological samples (Remote) OUTSTANDING, U20-S013. Detection of microbial (bacterial and mycoplasma) contamination, U20-S014. Hemocompatibility: haemolysis, platelet aggregation, plasma coagulation times, and complement activation, U20-S015. Cytotoxicity: proliferation, LDH, apoptosis, and ROS

U20	3571	U20-S02. Animal models in oncology (Remote) OUTSTANDING, U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING
U20	3524	U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING
U20	3543	U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING, U20-S12. Immunohistochemistry on histological samples (Remote) OUTSTANDING
U20	3593	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING, U20-S04. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING, U20-S05. In vivo Toxicology (On-site&Remote) OUTSTANDING, U20-S06. In vivo ADME and biodistribution assays (Remote) OUTSTANDING, U20-S07. In vivo PK/PD assays (Remote) OUTSTANDING
U20	3602	U20-S06. In vivo ADME and biodistribution assays (Remote) OUTSTANDING
U20	3618	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING, U20-S04. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING, U20-S05. In vivo Toxicology (On-site&Remote) OUTSTANDING, U20-S07. In vivo PK/PD assays (Remote) OUTSTANDING, U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING, U20-S12. Immunohistochemistry on histological samples (Remote) OUTSTANDING
U20	3693	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING, U20-S04. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING, U20-S05. In vivo Toxicology (On-site&Remote) OUTSTANDING, U20-S06. In vivo ADME and biodistribution assays (Remote) OUTSTANDING, U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING, U20-S12. Immunohistochemistry on histological samples (Remote) OUTSTANDING
U20	3695	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING, U20-S04. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING, U20-S05. In vivo Toxicology (On-site&Remote) OUTSTANDING, U20-S06. In vivo ADME and biodistribution assays (Remote) OUTSTANDING, U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING, U20-S12. Immunohistochemistry on histological samples (Remote) OUTSTANDING
U20	3726	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S02. Animal models in oncology (Remote) OUTSTANDING, U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING, U20-S04. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING, U20-S05. In vivo Toxicology (On-site&Remote) OUTSTANDING, U20-S07. In vivo PK/PD assays (Remote) OUTSTANDING, U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING, U20-S12. Immunohistochemistry on histological samples (Remote) OUTSTANDING
U20	3727	U20-S015. Cytotoxicity: proliferation, LDH, apoptosis, and ROS
U20	3525	U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING, U20-S12. Immunohistochemistry on histological samples (Remote) OUTSTANDING

U20	3526	U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING, U20-S12. Immunohistochemistry on histological samples (Remote) OUTSTANDING
U20	3527	U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING
U20	3533	U20-S015. Cytotoxicity: proliferation, LDH, apoptosis, and ROS

Unidad	Solicitud	Descripción Acceso
U21 (con U22, U24)	3515	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING
U21 (con U22, U24)	3600	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING
U21 (con U14, U22, U24)	3517	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING
U21 (con U19, U22)	3623	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING
U21 (con U19, U22)	3624	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING
U21 (con U14, U19, U22, U24)	3585	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING
U21 (con U14, U19, U22, U24)	3586	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING
U21 (con U19, U22)	3648	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING
U21 (con U19, U22)	3649	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U22 (con U21, U24)	3515	U22-S01. Animal Housing (Remote) OUTSTANDING
U22 (con U21, U24)	3600	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote)
U22 (con U14, U19, U21, U24)	3517	U22-S01. Animal Housing (Remote) OUTSTANDING
U22 (con U19, U21)	3623	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote), U22-S03. In vivo toxicology in rodent and non-rodent species (On-site), U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site), U22-S05. In vivo PK/PD assays in rodent and non-rodent species (On-site), U22-S06. In vivo safety and Efficacy studies of nanomaterials, biomaterials, and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING, U22-S08. Dosing of test substances and non-clinical specimen drawing in rodent and non-rodent species (On-site) OUTSTANDING

U22 (con U19, U21)	3624	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote), U22-S03. In vivo toxicology in rodent and non-rodent species (On-site), U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site), U22-S05. In vivo PK/PD assays in rodent and non-rodent species (On-site), U22-S06. In vivo safety and Efficacy studies of nanomaterials, biomaterials, and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING, U22-S08. Dosing of test substances and nonclinical specimen drawing in rodent and non-rodent species (On-site) OUTSTANDING
U22 (con U14, U19, U21,U24)	3585	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote), U22-S03. In vivo toxicology in rodent and non-rodent species (On-site), U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site), U22-S05. In vivo PK/PD assays in rodent and non-rodent species (On-site), U22-S06. In vivo safety and Efficacy studies of nanomaterials, biomaterials, and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING, U22-S08. Dosing of test substances and non-clinical specimen drawing in rodent and non-rodent species (On-site) OUTSTANDING
U22 (con U14, U19, U21,U24)	3586	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and Efficacy studies of nanomaterials, biomaterials, and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING
U22 (con U14, U19, U21,U24)	3648	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote), U22-S03. In vivo toxicology in rodent and non-rodent species (On-site), U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site), U22-S05. In vivo PK/PD assays in rodent and non-rodent species (On-site), U22-S06. In vivo safety and Efficacy studies of nanomaterials, biomaterials, and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING, U22-S08. Dosing of test substances and non-clinical specimen drawing in rodent and non-rodent species (On-site) OUTSTANDING
U22 (con U14, U19, U21, U24)	3649	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote), U22-S03. In vivo toxicology in rodent and non-rodent species (On-site), U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site), U22-S05. In vivo PK/PD assays in rodent and non-rodent species (On-site), U22-S06. In vivo safety and Efficacy studies of nanomaterials, biomaterials, and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING, U22-S08. Dosing of test substances and non-clinical specimen drawing in rodent and non-rodent species (On-site) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U24 (con U22, U21)	3515	U24-S02. Medical Imaging for Minimum Invasive Surgery
U24 (con U22, U21)	3600	U24-S01. Evaluation of therapies for cardiovascular disease, U24-S02. Medical Imaging for Minimum Invasive Surgery

U24 (con U14, U22, U21)	3517	U24-S01. Evaluation of therapies for cardiovascular disease
U24 (con U14, U19, U22, U21)	3585	U24-S01. Evaluation of therapies for cardiovascular disease, U24-S02. Medical Imaging for Minimum Invasive Surgery
U24 (con U14, U19, U22, U21)	3586	U24-S01. Evaluation of therapies for cardiovascular disease, U24-S02. Medical Imaging for Minimum Invasive Surgery

Unidad	Solicitud	Descripción Acceso
U25	3575	U25-S05. Preclinical horizontal spectrometer Biospec 7T (On-site&Remote) OUTSTANDING
U25	3541	U25-S03. NMR spectrometer 400 MHz with HRMAS/CPMAS probes (On-site&Remote) OUTSTANDING
U25	3601	U25-S05. Preclinical horizontal spectrometer Biospec 7T (On-site&Remote) OUTSTANDING
U25	3630	U25-S05. Preclinical horizontal spectrometer Biospec 7T (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U26	3629	U26-S06. Biomedical and metabolomic imaging (On-site)
U26	3634	U26-S06. Biomedical and metabolomic imaging (On-site)
U26	3553	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
U26	3546	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
U26	3610	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
U26	3554	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
U26	3583	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
U26	3595	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING, U26-S05. Training Advice and assistance (On-site&Remote)
U26	3597	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING, U26-S03. Metabolomic Studies (Remote) OUTSTANDING, U26-S05. Training Advice and assistance (On-site&Remote)

Unidad	Solicitud	Descripción Acceso
U27	3608	U27-S03. Biomedical signals processing, especially in cardiology (On-site & Remote) OUTSTANDING
U27	3609	U27-S01. Remote access to HPC (On-site&Remote)
U27	3613	U27-S01. Remote access to HPC (On-site&Remote)
U27	3614	U27-S01. Remote access to HPC (On-site&Remote)
U27	3635	U27-S01. Remote access to HPC (On-site&Remote)
U27	3639	U27-S03. Biomedical signals processing, especially in cardiology (On-site & Remote) OUTSTANDING
U27	3640	U27-S03. Biomedical signals processing, especially in cardiology (On-site & Remote) OUTSTANDING

U27	3644	U27-S03. Biomedical signals processing, especially in cardiology (On-site & Remote) OUTSTANDING
U27	3645	U27-S03. Biomedical signals processing, especially in cardiology (On-site & Remote) OUTSTANDING
U27	3646	U27-S01. Remote access to HPC (On-site&Remote)
U27	3647	U27-S01. Remote access to HPC (On-site&Remote), U27-S03. Biomedical signals processing, especially in cardiology (On-site & Remote) OUTSTANDING
U27	3656	U27-S01. Remote access to HPC (On-site&Remote), U27-S03. Biomedical signals processing, especially in cardiology (On-site & Remote) OUTSTANDING
U27	3658	U27-S01. Remote access to HPC (On-site&Remote)
U27	3659	U27-S01. Remote access to HPC (On-site&Remote)
U27	3660	U27-S01. Remote access to HPC (On-site&Remote)
U27	3661	U27-S01. Remote access to HPC (On-site&Remote), U27-S03. Biomedical signals processing, especially in cardiology (On-site & Remote) OUTSTANDING
U27	3663	U27-S01. Remote access to HPC (On-site&Remote), U27-S03. Biomedical signals processing, especially in cardiology (On-site & Remote) OUTSTANDING
U27	3665	U27-S01. Remote access to HPC (On-site&Remote), U27-S05. Massive parallel processing (On-site & Remote)
U27	3612	U27-S01. Remote access to HPC (On-site&Remote)
U27	3638	U27-S03. Biomedical signals processing, especially in cardiology (On-site & Remote) OUTSTANDING
U27	3642	U27-S01. Remote access to HPC (On-site&Remote)
U27	3652	U27-S01. Remote access to HPC (On-site&Remote)
U27	3657	U27-S01. Remote access to HPC (On-site&Remote), U27-S03. Biomedical signals processing, especially in cardiology (On-site & Remote) OUTSTANDING

Unidad	Solicitud	Descripción Acceso
U28	3520	U28-S04. High-resolution Liquid NMR (On-site & Remote) OUTSTANDING, U28-S05. High-resolution Magic Angle Spinning (HR-MAS) NMR (On-site & Remote), U28-S07. Transmission Electron Microscopy (TEM) (On-site & Remote), U28-S010. Scanning Electron Microscopy (SEM) (On-site & Remote), U28-S017. Multiphoton Microscopy (On-site & Remote) OUTSTANDING
U28	3521	U28-S04. High-resolution Liquid NMR (On-site & Remote) OUTSTANDING, U28-S05. High-resolution Magic Angle Spinning (HR-MAS) NMR (On-site & Remote), U28-S07. Transmission Electron Microscopy (TEM) (On-site & Remote), U28-S010. Scanning Electron Microscopy (SEM) (On-site & Remote), U28-S017. Multiphoton Microscopy (On-site & Remote) OUTSTANDING
U28	3534	U28-S08. Cryo-TEM (On-site & Remote) OUTSTANDING, U28-S010. Scanning Electron Microscopy (SEM) (On-site & Remote), U28-S015. Sample vitrification (On-site & Remote) OUTSTANDING, U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S017. Multiphoton Microscopy (On-site & Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (On-site & Remote)
U28	3539	U28-S01. Magnetic Resonance Imaging (MRI) (On-site & Remote) OUTSTANDING, U28-S04. High-Resolution Liquid NMR (On-site & Remote) OUTSTANDING, U28-S05. High-Resolution Magic Angle Spinning (HR-MAS) NMR (On-site & Remote), U28-S07. Transmission Electron Microscopy (TEM) (On-site & Remote), U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (On-site & Remote)

U28	3547	U28-S02. Fluorescent and Bioluminescent Optical Imaging (On-site & Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (On-site & Remote), U28-S08. Cryo-TEM (On-site & Remote) OUTSTANDING, U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (On-site & Remote), U28-S020. High Content Screening (On-site & Remote) OUTSTANDING
U28	3566	U28-S07. Transmission Electron Microscopy (TEM) (On-site & Remote), U28-S012. Cryo-ultramicrotomy (On-site & Remote) OUTSTANDING, U28-S013. High-pressure freezing (On-site & Remote) OUTSTANDING, U28-S014. Freeze substitution (On-site & Remote) OUTSTANDING
U28	3569	U28-S01. Magnetic Resonance Imaging (MRI) (On-site & Remote) OUTSTANDING, U28-S02. Fluorescent and Bioluminescent Optical Imaging (On-site & Remote) OUTSTANDING, U28-S03. Computed Tomography (CT) (On-site & Remote), U28-S04. High-resolution Liquid NMR (On-site & Remote) OUTSTANDING, U28-S05. High-resolution Magic Angle Spinning (HR-MAS) NMR (On-site & Remote), U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S020. High Content Screening (On-site & Remote) OUTSTANDING
U28	3615	U28-S01. Magnetic Resonance Imaging (MRI) (On-site & Remote) OUTSTANDING, U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S017. Multiphoton Microscopy (On-site & Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (On-site & Remote)
U28	3616	U28-S02. Fluorescent and Bioluminescent Optical Imaging (On-site & Remote) OUTSTANDING, U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S020. High Content Screening (On-site & Remote) OUTSTANDING
U28	3617	U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S018. Super-resolution Microscopy (On-site & Remote) OUTSTANDING, U28-S020. High Content Screening (On-site & Remote) OUTSTANDING
U28	3650	U28-S02. Fluorescent and Bioluminescent Optical Imaging (On-site & Remote) OUTSTANDING
U28	3672	U28-S01. Magnetic Resonance Imaging (MRI) (On-site & Remote) OUTSTANDING, U28-S04. High-Resolution Liquid NMR (On-site & Remote) OUTSTANDING, U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (On-site & Remote), U28-S020. High Content Screening (On-site & Remote) OUTSTANDING, U28-S021. Nuclear Molecular Imaging (PET/SPECT/CT) (On-site & Remote)
U28	3682	U28-S08. Cryo-TEM (On-site & Remote) OUTSTANDING, U28-S010. Scanning Electron Microscopy (SEM)(On-site & Remote), U28-S015. Sample vitrification (On-site & Remote) OUTSTANDING, U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S017. Multiphoton Microscopy (On-site & Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (On-site & Remote)
U28	3683	U28-S07. Transmission Electron Microscopy (TEM)(On-site & Remote)
U28	3684	U28-S02. Fluorescent and Bioluminescent Optical Imaging (On-site & Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (On-site & Remote), U28-S010. Scanning Electron Microscopy (SEM) (On-site & Remote), U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S017. Multiphoton Microscopy (On-site & Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (On-site & Remote), U28-S021. Nuclear Molecular Imaging (PET/SPECT/CT) (On-site & Remote)

U28	3685	U28-S04. High-Resolution Liquid NMR (On-site & Remote) OUTSTANDING, U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (On-site & Remote)
U28	3686	U28-S04. High-Resolution Liquid NMR (On-site & Remote) OUTSTANDING, U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING
U28	3688	U28-S04. High-Resolution Liquid NMR (On-site & Remote) OUTSTANDING
U28	3687	U28-S04. High-Resolution Liquid NMR (On-site & Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (On-site & Remote), U28-S010. Scanning Electron Microscopy (SEM) (On-site & Remote), U28-S011. Environmental SEM (ESEM) (On-site & Remote) OUTSTANDING, U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (On-site & Remote)

Unidad	Solicitud	Descripción Acceso
U29	3573	U29-S01. Synthesis of oligonucleotides and characterization (On-site & Remote). OUTSTANDING
U29	3574	U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING, U29-S03. Special nucleotides for oligonucleotide synthesis. (Remote) OUTSTANDING.
U29	3579	U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING

7 de marzo de 2024

Comité de Coordinación de NANBIOSIS